]>
IRCT20211205053277N1 IRCT 2023-07-31 Tehran University of Medical Sciences Evaluation of the effect of Montelukast in allergic rhinitis, Evaluation of the effect of neotadine in the treatment of allergic rhinitis TMNS Comparison of the effect of montelukast with the usual dose of twice as much neotadine with intranasal mometasone in allergic rhinitis 2023-05-02 anticipated 60 Complete https://irct.ir/trial/60408 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were equally assigned to 4 groups using the permuted block method. In this way, each treatment group was assigned a code (the codes are A for the group receiving neotadine once a day, B for receiving neotadine twice a day, C for receiving montelukast and D for the group receiving neotadine and Montelukast). Then, a random number from 1 to 24 was assigned to different states of the blocks (ABCD, ABDC, ACDB,...), which were 24 states in total. After that, using the Random Sequence Generator software, random numbers were obtained and the order of the blocks in a list was determined. The blocks and numbers are as follows: ABCD for number 1, ABDC for number 2, ACBD for number 3, ACDB for number 4, ADBC ​​for number 5, ADCB for number 6, BACD for number 7, BADC for number 8, BCAD for number 9, BCDA for number 10, BDAC for number 11, DBAC for number 12, BDCA for number 13, CABD for number 14, CADB for number 15, CDAB for number 16, CDBA for number 17, CBAD for number 18, CBDA for number 19, DABC for number 20, DACB for number 21, DCAB for number 22, DCBA for number 23, DBCA for number 24,((It should be noted that this list is predetermined and after the sample size is determined, the allocation will be done up to the fifteenth block of 4 according to the number of samples in each group. In this way, 15 people will be included in each group.). 2-3 allergic rhinitis. Intervention 1: The patients in the first group will be treated by mometasone nasal spray with a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with 5 mg desloratadine tablets every night for 8 weeks by a specialist. Intervention 2: Patients in the second group will be treated by mometasone nasal spray with a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with 5 mg desloratadine (Neotadine) 1 tablet twice a day for 8 weeks by a specialist. Intervention 3: Patients in the third group will be treated with mometasone nasal spray at a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with oral Montelukast tablets 5 mg daily for two months. Intervention 4: Patients in the fourth group will be treated with mometasone nasal spray at a dose of 100 micrograms (two puffs in each nostril) daily for 8 weeks, along with 5 mg oral Montelukast tablets and 1 desloratadine tablet for 8 weeks. Yes - There is a plan to make this available What will be shared: The informed consent form and data analysis spss file will be shared. When: Access starts 6 months after results are published To whom: The data will be available to academic and scientific institutions Conditions: In order to be used in scientific articles and the optimal use of drugs in the course of treatment Where to obtain: Refer to Bahrami Hospital and the people whose names are given in this plan How to obtain: The people named in this plan should be emailed as information will be available as soon as possible Comments: ...
public Dr Niloufar Ghanbari
Sabalan street , AnsarAlhosein Ave
tehran Iran (Islamic Republic of) 1641744991 +98 21 7756 8801 niloufargh67@yahoo.com Tehran University of Medical Sciences scientific Dr Alireza Shafii
Sabalan street , Ansaralhosein Ave
tehran Iran (Islamic Republic of) 1641744991 +98 21 7301 3000 ar.shafii@gmail.com Tehran University of Medical Sciences Iran (Islamic Republic of) Having moderate to severe allergic rhinitis over 6 years of age having informed consent 6 years no limit Both Asthma infection and adenoid hypertrophy Patients with chronic diseases Antihistamine use during the last 1 month Systemic or topical corticosteroids History of neotadine allergy J30.89 Other allergic rhinitis Treatment - Drugs Treatment - Drugs Treatment - Drugs Treatment - Drugs The patients in the first group will be treated by mometasone nasal spray with a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with 5 mg desloratadine tablets every night for 8 weeks by a specialist. Patients in the second group will be treated by mometasone nasal spray with a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with 5 mg desloratadine (Neotadine) 1 tablet twice a day for 8 weeks by a specialist. Patients in the third group will be treated with mometasone nasal spray at a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with oral Montelukast tablets 5 mg daily for two months. Patients in the fourth group will be treated with mometasone nasal spray at a dose of 100 micrograms (two puffs in each nostril) daily for 8 weeks, along with 5 mg oral Montelukast tablets and 1 desloratadine tablet for 8 weeks. Nasal symptom score. Timepoint: before treatment intervention and two months after treatment. Method of measurement: Nasal symptom scoring table. Tehran University of Medical Scince Approved 2022-04-23 national system of ethics in biomedical research Bahrami hospital , Ansaralhosein ave , south Sabalan , Tehran tehran Tehran Iran (Islamic Republic of)